| Inception – Discovery Stage Research Projects | Cedars-Sinai Medical Center | Blood Brain Barrier (BBB)-on-Chip: Development and validation of a novel iPS-based microfluidic model of the human BBB |
$241,992 |
| Clinical Trial Stage Projects | Cedars-Sinai Medical Center | CNS10-NPC-GDNF delivered into the motor cortex for the treatment of ALS |
$11,990,372 |
| Clinical Trial Stage Projects | Cedars-Sinai Medical Center | Clinical Study to Assess Safety and Efficacy of Subretinal Injection of Human Neural Progenitor Cells for Treatment of Retinitis Pigmentosa |
$10,444,063 |
| Clinical Trial Stage Projects | Cedars-Sinai Medical Center | Human Neural Progenitors Secreting Glial Cell Line-Derived Neurotrophic Factor (CNS10-NPC-GDNF) for the Treatment of Amyotrophic Lateral Sclerosis |
$6,154,067 |
| Conference | Cedars-Sinai Medical Center | California ALS Summit 2012 |
$6,825 |
| iPSC Consortia Award | Cedars-Sinai Medical Center | The HD iPSC Consortium: Repeat Length Dependent Phenotypes for Assay Development |
$300,000 |
| Disease Team Therapy Development – Research | Cedars-Sinai Medical Center | Progenitor Cells Secreting GDNF for the Treatment of ALS |
$16,168,464 |
| Disease Team Therapy Planning I | Cedars-Sinai Medical Center | Stem Cells Secreting GDNF for the Treatment of ALS |
$63,487 |
| Tools and Technologies II | Cedars-Sinai Medical Center | Use of iPS cells (iPSCs) to develop novels tools for the treatment of spinal muscular atrophy. |
$1,933,022 |
